The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

Congestive Heart Failure Treatment Market Predicted Growth At 4.47% CAGR To 35.5 Billion USD By 2032 Gilead Sciences The Global Congestive Heart Failure Treatment market is witnessing significant ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

Janney Montgomery Scott LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 47.0% ...